In a 68‑year‑old obese woman with hyperuricemia, mildly elevated transaminases and Langerhans‑cell histiocytosis who has exocrine pancreatic insufficiency, which pancreatic enzymes are required for replacement therapy?

Pancreatic Enzyme Replacement Therapy for Exocrine Pancreatic Insufficiency

For this 68-year-old woman with exocrine pancreatic insufficiency, pancreatic enzyme replacement therapy (PERT) containing lipase, protease, and amylase derived from porcine sources is required, with an initial dose of at least 40,000 USP units of lipase per meal and 20,000 USP units with snacks. 1

Essential Enzyme Components

All FDA-approved PERT formulations contain three critical pancreatic enzymes: 1

• Lipase - the most critical enzyme for fat digestion
• Protease - for protein digestion
• Amylase - for carbohydrate digestion

The focus of PERT dosing centers on lipase content because humans lack alternative mechanisms for fat digestion, whereas protein and carbohydrate digestion have backup intestinal mechanisms. 1

Specific Dosing Recommendations

Initial Dosing

Start with at least 40,000 USP units of lipase during each meal in adults, and half that amount (20,000 USP units) with snacks. 1 This translates to approximately 500 units of lipase per kg per meal for an 80 kg patient. 1

Dose Titration

The dose should be adjusted upward based on meal size and fat content, with a maximum of 2,500 units of lipase per kg per meal or 10,000 units of lipase per kg per day. 1 Most patients will reduce steatorrhea to less than 15 g fat per day with 25,000-40,000 IU of lipase per meal, though some may require larger doses. 2

Available PERT Formulations

All commercially available PERT products are derived from porcine sources and are equally effective at equivalent lipase doses. 1 FDA-approved options include: 1

• Creon (enteric-coated microspheres): 3,000/6,000/12,000/24,000/36,000 USP units lipase
• Zenpep (enteric-coated beads): 3,000/5,000/10,000/15,000/20,000/25,000/40,000 USP units lipase
• Pancreaze (enteric-coated microtablets): 2,600/4,200/10,500/16,800/21,000/37,000 USP units lipase
• Pertzye (enteric-coated microspheres): 4,000/8,000/16,000/24,000 USP units lipase
• Viokace (non-enteric-coated tablets): 10,444/20,880 USP units lipase

Critical Administration Guidelines

Timing

PERT must be taken during the meal, not before or after, to maximize mixing and digestion of nutrients. 1 For enteric-coated preparations, consider starting administration just prior to the meal so enzymes are available during the first postprandial hour when considerable lipid empties from the stomach. 3

Acid Suppression

Non-enteric-coated preparations (Viokace) require co-administration with H2 receptor antagonists or proton pump inhibitors to prevent acid denaturation of lipase. 1 Enteric-coated preparations do not require acid suppression, though many patients benefit from it to improve PERT efficacy. 1

Essential Adjunctive Therapy

Routine supplementation and monitoring of fat-soluble vitamins (A, D, E, K) are required. 1 Fat-soluble vitamin deficiencies are a hallmark of untreated EPI and persist even with PERT. 1 Vitamin D and K deficiencies are associated with osteopathy and fractures in chronic pancreatitis, and treatment reduces bone fracture rates. 1

Monitoring Treatment Success

Successful PERT treatment is measured by: 1

• Reduction in steatorrhea and gastrointestinal symptoms
• Weight gain and improved muscle mass and function
• Improvement in fat-soluble vitamin levels
• Improved body mass index

Baseline measurements should include: 1

• Body mass index and quality-of-life measures
• Fat-soluble vitamin levels
• Dual-energy x-ray absorptiometry scan (repeated every 1-2 years)

Common Pitfalls to Avoid

Do not use over-the-counter pancreatic enzyme supplements - these are classified as dietary supplements only, are not standardized or regulated, and have unknown efficacy and safety. 1

Avoid very-low-fat diets - dietary modifications should include a low-moderate fat diet with frequent smaller meals, but very-low-fat diets should be avoided as they can worsen nutritional status. 1

Do not rely on therapeutic trials for diagnosis - response to PERT is unreliable for diagnosing EPI and should not be used as a diagnostic tool. 1

Clinical Context for This Patient

Given this patient's Langerhans-cell histiocytosis, obesity, and metabolic abnormalities, untreated EPI will result in complications related to fat malabsorption and malnutrition, negatively impacting quality of life and potentially mortality. 1 The obesity does not preclude the need for PERT, as patients with EPI can be obese and still have sarcopenia and micronutrient deficiencies. 1